Evidence map›Paper›PMID 39655096›Full record

ReviewLaryngoscope investigative otolaryngology2024

Efficiency of gene therapy for sensorineural hearing loss in mouse model: A meta-analysis.

Nevra Keskin Yilmaz, Dogukan Ozen, Rafael da Costa Monsanto, Emre Ocak, Artur Koerig Schuster, Tomotaka Shimura, Sebahattin Cureoglu

Abstract readReview
In one paragraph

Review in Laryngoscope investigative otolaryngology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nevra Keskin YilmazDepartment of Internal Medicine Faculty of Veterinary Medicine, Ankara University Ankara Turkey.ORCID https://orcid.org/0000-0002-6287-1157
Dogukan OzenDepartment of Biostatistics Faculty of Veterinary Medicine, Ankara University Ankara Turkey.ORCID https://orcid.org/0000-0003-1943-2690
Rafael da Costa MonsantoDepartment of Otolaryngology Head & Neck Surgery University of Minnesota Minneapolis Minnesota USA.ORCID https://orcid.org/0000-0002-9124-593X
Emre OcakDepartment of Otolaryngology Head & Neck Surgery Faculty of Medicine, Ankara University Ankara Turkey.ORCID https://orcid.org/0000-0003-0652-2777
Artur Koerig SchusterPostgraduate Program in Medicine: Surgical Sciences, Universidade Federal do Rio Grande do Sul (UFRGS) Porto Alegre RS Brazil.ORCID https://orcid.org/0000-0002-1431-3855
Tomotaka ShimuraDepartment of Otolaryngology Head & Neck Surgery University of Minnesota Minneapolis Minnesota USA.ORCID https://orcid.org/0000-0003-1164-6977
Sebahattin CureogluDepartment of Otolaryngology Head & Neck Surgery University of Minnesota Minneapolis Minnesota USA.ORCID https://orcid.org/0000-0001-9220-7073

Funding

Resource Center for Human Temporal Bone Research, Innovation, and EducationU24DC020851 · NIDCD · UNIVERSITY OF MINNESOTA · PI Meredith Evelyn Adams, SEBAHATTIN CUREOGLU · 2022 to 2026
$4.6M
NIDCD NIH HHS U24 DC020851
6 · The paper itself

Abstract

Objectives: Sensorineural hearing loss (SNHL) is a disorder characterized by the loss or impairment of cochlear hair cells or the auditory nerve. In recent years, gene therapy has emerged as a promising approach for SNHL treatment. The objective of this study is to evaluate the impact of gene therapy on the restoration or improvement of auditory function in mouse model with loss or impairment of hearing. Methods: Studies with clear experimental designs, and auditory brainstem response (ABR) analysis as relevant outcome measures were included by searching PubMed, Scopus, and Web of Science databases. The PRISMA guideline was used for abstracting data and assessing data quality and validity. A quantitative synthesis was performed using a random effects model to examine the effect of gene therapy on auditory function in SNHL. Results: Nine articles including 71 studies meeting the inclusion criteria were identified. These studies explored therapies targeting the TMC1, VGLUT3, USH1C, CLRN1, WHRN, and PJVK genes, with genetic material ranging from 1.8 × 10 Conclusions: Although promising results have been obtained regarding the potential success of gene therapy in SNHL, further investigation is needed to explore the long-term effects of gene therapy, treatment response rates, and the relationships between different genetic mutation types.

Indexed as

gene therapymeta‐analysismicesensorineural hearing loss

Identifiers

PMID39655096
PMCPMC11626480

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.